共查询到20条相似文献,搜索用时 234 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
《Expert opinion on biological therapy》2013,13(12):1823-1829
Background: Contrast enhancing lesions (CELs) in MRI represent inflammatory events in multiple sclerosis (MS). IFN-β-1b decreases the formation of CELs. However, the ability of IFN-β-1b to reduce the size of CELs arising during therapy has not been extensively investigated. Methods: Thirty patients with relapsing-remitting (RR) MS were followed for a 3-month pre-therapy phase then for a 6-month therapy phase during which treatment with IFN-β-1b at a dosage of 250 μg subcutaneously injected every other day was employed. Each patient underwent monthly clinical and MRI examinations. For all patients, CELs were identified on postcontrast T1-weighted MRIs. CEL number, size, and volume were computed using Medx software. Results: The average number and total lesion volume of CELs visible during the therapy phase were significantly lower than the number and total lesion volume of CELs observed in the pre-therapy phase. However, there was no significant reduction between pre-therapy and therapy phases in the mean size of individual lesions arising during the respective phases. Conclusions: Since size of CELs has been related to severity of tissue damage, the lack of size decrease during therapy suggested a limited therapeutic effect of IFN-β-1b if a blood–brain barrier breakdown has occurred. 相似文献
12.
背景:核磁共振成像的定量测量已被广泛用于评估多发性硬化症的治疗效果。目的:确定是否干扰素β-1b对多发性硬化脑萎缩的影响能通过MRI测量表达出来。设计:随机对照观察。单位:日本京都宇多野病院神经疾病研究中心。对象:选择1998-01/12在在日本京都宇多野病院神经疾病研究中心收治的188例多发性硬化患者,男55例,女133例,年龄16~59岁,平均(36±11)岁。纳入标准:①按poser再发缓解型诊断标准临床确诊为多发性硬化。②扩展残疾状况评分表得分≤7分。③在过去的1年中至少1次复发,或在就诊之前的2年间有至少2次复发,但就诊前30d无复发,神经系统体征稳定至少1个月,干扰素β-1b皮试阴性。④均对检测项目知情同意。纳入患者中,视神经脊髓型148例,经典型50例。方法:①药物治疗:所有患者给予干扰素β-1b注射剂,根据注射剂量不同将患者分为低剂量组(n=93)和高剂量组(n=95),分别给予160万U和800万U隔日干扰素β-1b注射剂皮下注射,共使用2年。②磁共振扫描检查:对所有患者包括病灶的部位(视神经、大脑、小脑、脑干和脊髓)进行磁共振扫描,T1和T2加权轴面磁共振检查由同一神经病学家评估,T2加权像病灶面积是逐层相加计算出总面积以mm2表示,检查指标为第三脑室、侧脑室宽度、脑宽度进行测量,结果采用萎缩率表示。③神经功能缺损检查:采用Kurtzke扩展残疾状况评分表(从0分到10分,0分为正常,分数越高病情越严重)评估。④相关因素分析:对148例典型多发性硬化患者脑萎缩情况和T2病灶面积和扩展残疾状况评分表得分变化两项因素进行相关性分析,同时对起始时变量(年龄,病程,复发率,T2病灶面积和扩展残疾状况评分表得分)和脑萎缩情况进行相关性分析。主要观察指标:①两组患者脑萎缩情况比较。②脑萎缩测量相关因素分析。结果:纳入198例患者全部进入结果分析。①两组患者脑萎缩情况比较结果:高剂量组经典型多发性硬化患者侧脑室宽度、三脑室宽度、脑宽度萎缩率分别是2.84%,3.15%和1.3%,明显低于低剂量组(4.09%,5.36%,1.97%,P<0.01)。高剂量组视神经脊髓型多发性硬化患者侧脑室宽度、三脑室宽度、脑宽度的萎缩率分别是0.9%,1.55%和0.6%,与低剂量组无明显差异(1.65%,1.75%,0.7%,P>0.05)。②经典型多发性硬化患者侧脑室宽度与T2病灶面积和EDSS得分均有明显相关性(r=0.33,0.27,P<0.01),三脑室宽度与T2病灶面积和EDSS得分有明显相关性(r=0.31,0.29,P<0.05),脑宽度与T2病灶面积和EDSS得分也有明显相关性(r=0.11,0.14,P<0.05),起始时EDSS得分和T2病灶面积变化与侧脑室宽度明显相关(r=0.23,0.33,P<0.05),其他起始时的参数未能显示出有意义的关系。结论:干扰素β-1b对脑萎缩的影响是有积极意义的,在高和低剂量组之间,有意义的差别被显示出来。脑萎缩测量提供了一个独立的关于干扰素β-1b治疗多发性硬化的肯定作用和剂量的影响。 相似文献
13.
目的 探究外周血同型半胱氨酸(homocysteine,Hcy)、视椎蛋白样蛋白1(visinin-like protein 1,VILIP- 1)、尿酸(uric acid,UA)与脑小血管病(cerebral small vessel disease,CSVD)患者病情程度及认知障碍相关性。方法 选取2017 年6 月~ 2019 年6 月沧州市人民医院医专院区70 例CSVD 患者作为观察组,同期选取30 例健康体检者作为对照组。统计两组及观察组不同神经功能、脑动脉搏动指数(PI)、有无认知障碍、外周血Hcy,VILIP-1 和UA 水平,通过Spearman 和多元线性回归模型分析外周血各指标与病情程度、认知障碍的关系。结果 ①观察组外周血VILIP-1(671.05±201.32 pg/ml),Hcy(20.83±6.25 μmol/L),UA(352.21±78.66 μmol/L)高于对照组(475.12±142.54pg/ml,10.05±3.02 μmol/L 和241.25±40.86 μmol/L), 差异均有统计学意义(t=4.831,8.989,7.698,均P < 0.05)。②观察组PI 重度者外周血UA(449.79±134.94μmol/L),Hcy(30.43±5.89μmol/L)和VILIP-1(876.94±263.08pg/ml)水平高于PI 轻中度者(273.46±82.04μmol/L,360.18±108.05μmol/L;15.33±4.60μmol/L,20.58±6.27μmol/L;502.51±150.75pg/ml,689.84±206.95pg/ml), 差异均有统计学意义(F=13.545~35.749,均P < 0.05)。观察组NIHSS评分外周血UA(443.70±133.11μmol/L),Hcy(28.33±5.46μmol/L),VILIP-1(941.35±282.41pg/ml)水平高于NIHSS 评分轻中度者(280.25±84.08μmol/L,372.59±111.78μmol/L;16.05±4.82μmol/L,21.42±5.91μmol/L;498.88±149.65pg/ml,692.27±207.61pg/ml),差异均有统计学意义(F=12.544~23.020,均P < 0.05)。③观察组认知障碍者UA(389.96±116.99μmol/L),Hcy(25.66±7.71μmol/L),VILIP-1(811.52±243.56pg/ml)水平高于无认知障碍者(301.88±90.56μmol/L,14.39±4.32μmol/L,483.76±145.13pg/ml),差异均有统计学意义(F=3.424~7.710,均P< 0.05)。④外周血Hcy,VILIP-1,UA与PI 呈正相关(r=0.836,0.883,0.728),与NIHSS 评分呈正相关(r=0.665,0.762,0.666),与认知障碍呈负相关(r=-0.591,0.635,0.599);在控制年龄、性别等其他因素后,外周血Hcy(标准化偏回归系数:0.277,1.122,-0.250),VILIP-1(标准化偏回归系数:0.638,0.304,-0.319),UA(标准化偏回归系数:0.251,0.656,-0.398)与PI 和NIHSS 评分、认知障碍显著相关(均P < 0.05)。结论 CSVD 患者外周血Hcy,VILIP-1 和UA 水平呈高表达,与病情程度、认知障碍密切相关。联合检测其水平变化有助于指导临床治疗。 相似文献
14.
目的 探讨氯沙坦对原发性高血压伴高尿酸血症(HUA)患者血清超敏C反应蛋白(hsCRP)和尿酸(UA)的影响及其安全性.方法 将80例高血压伴HUA患者随机分为氯沙坦组(40例)和硝苯地平组(40例),每组分别给予氯沙坦50 mg/d、硝苯地平控释片30 mg/d口服,连续治疗6个月,检测用药前、后血清hs-CRP、UA、肝肾功能、血肌酸磷酸激酶(CK)浓度及血压的变化.结果 与治疗前比较,治疗6个月后氯沙坦组与硝苯地平组的收缩压(SBP)、舒张压(DBP)均显著降低[氯沙坦组收缩压由(158.5±13.2) mmHg降至(136.7±9.4) mmHg,t=3.50,P< 0.01;舒张压由(95.6±8.4) mmHg降至(83.3±6.4) mmHg,t=3.49,P< 0.01;硝苯地平组收缩压:(157.7 ±13.9) mmHg降至(134.6±8.2)mmHg,t=3.53,P< 0.01;舒张压:(96.1 ±8.9)mmHg降至(81.2 ±6.8)mmHg,t=3.56,P< 0.01],但组间比较差异无统计学意义.氯沙坦组的血清hs-CRP、UA浓度较用药前明显下降,差异均有统计学意义[氯沙坦组hs-CRP:(5.68±1.53) mg/L降至(3.52±0.57) mg/L,t=3.82,P< 0.01;UA:(502 ±45)μmol/L降至(450 ±38) μmol/L,t=3.48,P<0.01];而硝苯地平组血清hs-CRP、UA浓度较用药前无明显变化[血清hs-CRP:(5.61±1.64) mg/L降至(5.33±1.48) mg/L,t=1.34,P> 0.05;UA:(499 ±43)μmol/L降至(489 ±42) μmol/L,t=0.68,P> 0.05].氯沙坦组患者服药前后肝肾功能、CK的变化均无显著差异,未发生严重不良事件.结论 氯沙坦能降低原发性高血压伴HUA患者的血清hs-CRP、UA浓度,治疗期间无严重不良反应,安全性良好. 相似文献
15.
目的探讨蒙古族原发性高血压患者血尿酸水平与早期肾损害的关系和可能机制。方法选择蒙古族高血压患者86例,汉族高血压患者89例,分别采用尿素酶法测定血尿酸(UA)免疫比浊法测定胱抑素C(Cys-C)、13:微球蛋白(β2m),进行比较分析。结果蒙古族高血压组UA(456.32±45.49)μmol/L显著高于汉族高血压组(456.32±45.49)比UA(385.30±37.85)μmol/L(P〈0.05)。蒙古族组及汉族组UA与Cys·C、β2m均呈正相关(r=0.714、0.694;r=0.624、0.526;P〈0.05),在Cer〈50ml/min时,Cer与Ca(r=0.72)、Cys—C(r=0.68)、β2m(r=0.75),SCr(r=0.65)均有较好相关性呈正相关,r分别为0.72、0.68、0.75、0.65。Ccr为50~80ml/min时,Cer与UA、Cys.C、β2m的相关性,r分别为0.75、0.73、0.70,而Cer与SCr的r值为0.55。结论 蒙古族高血压人群高尿酸血症患者更容易出现肾损害。 相似文献
16.
目的观察结肠透析联合保留灌肠治疗慢性肾衰竭的临床疗效。方法将我院109例慢性肾衰竭患者(血肌酐〉133μmol/L未进行血液透析或腹膜透析者)且结肠透析次数〉5次(2~3次/周)观察2周。其中将应用结肠透析联合保留灌肠治疗的69例慢性肾衰竭患者定为治疗组(其中血肌酐值在〉500~1 167μmol/L范围31例,血肌酐值在133~500μmol/L范围38例)。将只应用药用炭胶囊或尿毒清颗粒保留灌肠(1次/d)的40例患者定为对照组,其中应用药用炭胶囊灌肠组20例,应用尿毒清灌肠组20例。均共观察2周。分别观察两组治疗前后的临床症状、血肌酐、尿素氮、血磷、血尿酸来观察结肠透析联合保留灌肠的疗效。结果①所有患者食欲不振、恶心呕吐、乏力症状改善明显。②所有患者经治疗后血肌酐、尿素氮、血磷、血尿酸均较前改善,且结肠透析联合保留灌肠组疗效明显优于只应用尿毒清或药用炭灌肠组(P〈0.05)。③治疗组中所有患者经治疗后血肌酐、尿素氮、血磷、血尿酸均显著下降,差异有统计学意义(P〈0.05),而血肌酐133~500μmol/L组与血肌酐〉500~1 167μmol/L组相比,对于血肌酐及尿素氮的降低疗效更显著,差异有统计学意义(P〈0.05),而对于血磷及血尿酸的改变差异无统计学意义(P〉0.05)。结论①与单纯保留灌肠相比,结肠透析联合保留灌肠对于改善慢性肾衰竭患者的临床症状以及对血肌酐、尿素氮、血磷、尿酸的降低均有较明显的效果;②结肠透析联合保留灌肠尤其对于早、中期(血肌酐值在133~500μmol/L范围)慢性肾衰竭患者的疗效更为显著;③结肠透析联合保留灌肠治疗慢性肾衰竭的过程中未出现任何不良反应,且疗效确切。 相似文献
17.
【目的】探讨熊果酸(Ursolic acid,UA)对人卵巢癌 SKOV3细胞增殖与凋亡的影响。【方法】常规培养人卵巢癌 SKOV3细胞,应用 UA 浓度为5、10、20、40和80μmol/L 分别干预12 h、24 h 和48 h,采用 MTT 法检测细胞增殖;采用流式细胞仪检测细胞凋亡和细胞周期变化,应用 Western blot 技术检测细胞周期相关蛋白 P21、CyclinD1的表达水平。【结果】与空白对照组(0μmol/L UA)比较,40和80μmol/L UA 分别作用 SKOV3细胞12 h、24 h 和48 h 后 OD 值均显著降低(P <0.05);10、20和40μmol/L UA 作用24 h 后 SKOV3细胞早期凋亡率、晚期凋亡率和 G0/G1期比率较对照组升高,20和40μmol/L UA 作用24 h 后 SKOV3细胞周期蛋白 Cyclin D1明显降低而 P21水平显著升高(P <0.05)。【结论】体外实验中,UA 可抑制人卵巢癌 SKOV3细胞增殖和促其凋亡,其机制可能与细胞周期蛋白 Cyclin D1表达降低和 P21表达升高有关。 相似文献
18.
刘大勇 《实用临床医药杂志》2011,15(9)
目的测定急性冠脉综合征(ACS)患者血清同型半胱氨酸(Hcy)和C-反应蛋白(CRP)水平,探讨血清Hcy、CRP水平与ACS严重程度的关系。方法将124例ACS患者分为不稳定性心绞痛(UA)组(66例)和急性心肌梗塞(AMI)组(58例),以57名健康体检者作为对照。测定各组血清Hcy、CRP水平,并进行统计学分析。结果血清Hcy水平UA组(16.08±5.17)μmol/L、AMI组(21.67±7.38)μmol/L,与对照组(10.11±4.15)μmol/L比较差异有统计学意义(P<0.05),UA组与AMI组比较,差异有统计学意义(P<0.05)。CRP水平UA组(29.65±15.87)mg/L、AMI组(58.14±21.17)mg/L,与对照组(8.06±4.86)mg/L比较差异有统计学意义(P<0.01),UA组与AMI组比较,差异有统计学意义(P<0.05)。结论 ACS患者血清Hcy、CRP水平显著高于正常人群,测定血清Hcy、CRP水平可能对ACS的预防和治疗监测具有重要临床意义。 相似文献
19.
Body composition in ambulatory women with multiple sclerosis 总被引:2,自引:0,他引:2
Lambert CP Lee Archer R Evans WJ 《Archives of physical medicine and rehabilitation》2002,83(11):1559-1561
OBJECTIVE: To compare whole-body fat mass and fat-free mass (FFM) in ambulatory patients with multiple sclerosis (MS) and control subjects without MS. DESIGN: Nonrandomized controlled trial or cross-sectional study. SETTING: An exercise physiology laboratory at a medical school. PARTICIPANTS: Seventeen ambulatory patients with MS and 12 control subjects (all subjects were women). The median Expanded Disability Status Scale (EDSS) score was 4.0 for the individuals with MS. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Whole-body percentage of fat-free mass (%FFM), percentage of body fat (%BF), FFM, and fat mass. RESULTS: A significant difference in age was observed between the groups; thus, age was used as a covariate in the body composition analyses. No significant differences were observed between the groups in %BF: 32.5+/-13.9 and 27.8+/-5.6 (P=.54) for MS and controls, respectively, or %FFM, 67.1+/-14.9 and 71.3+/-12.4 (P=.42) for MS and controls, respectively. For individuals with MS, no significant relation was observed between EDSS score and %BF (P=.24) or between EDSS score and %FFM (P=.24). CONCLUSION: No significant differences were observed in body composition between ambulatory MS patients and controls. Furthermore, the EDSS score was not a significant predictor of %BF or %FFM for people with MS. 相似文献
20.
Eleni Leonidou Marios Pantzaris Maria A. Loizidou Theodoros Kyriakides Yiolanda P. Christou 《Postgraduate medicine》2013,125(7):486-489
Objective: The objective of this study was to evaluate the efficacy and safety of rituximab (RTX) treatment given off-label to Cypriot patients with multiple sclerosis (MS).Methods: Clinical data from 30 MS patients ever treated with off-label RTX until mid-2018 at the Cyprus Institute of Neurology and Genetics were retrospectively collected and reviewed. The heterogeneous patient cohort included patients with relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). Outcome data (relapse rate and EDSS progression) as well as adverse effects for patients with a follow-up period of >12 months (n = 13) were recorded.Results: Following RTX administration, all patients with RRMS remained relapse free and had a stable or slightly improved EDSS score (mean EDSS before treatment = 6, mean EDSS at 12 months = 4.75). Patients with SPMS had a significant reduction in their relapse rate and a stabilization or slight improvement of their EDSS scores (mean EDSS before treatment = 6.25, mean EDSS at 12 months = 5.5). Only one of the patients with PPMS had a follow-up period of >12 months and his EDSS score remained unchanged. Rituximab infusions were generally well tolerated; there were only seven grade 3 or 4 adverse events recorded.Conclusion: Our results are in agreement with larger retrospective studies in which it was demonstrated that RTX was well tolerated and effective in treating RRMS and SPMS patients by reducing relapse rate and stabilizing disease. 相似文献